The long-term effects of antipsychotic medication on clinical course in schizophrenia

American Journal of Psychiatry

Volumn 174, Issue 9, 2017, Pages 840-849

  Goff, Donald C ^{a,b,c,d,e,f,g}   Falkai, Peter ^{a,b,c,d,e,f,g}   Fleischhacker, W Wolfgang ^{a,b,c,d,e,f,g}   Girgis, Ragy R ^{a,b,c,d,e,f,g}   Kahn, Rene M ^{a,b,c,d,e,f,g}   Uchida, Hiroyuki ^{a,b,c,d,e,f,g}   Zhao, Jingping ^{a,b,c,d,e,f,g}   Lieberman, Jeffrey A ^{a,b,c,d,e,f,g}  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d NewYork Presbyterian Columbia University Irving Medical Center   (United States)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

BRAIN SIZE; CHRONIC DRUG ADMINISTRATION; DRUG EFFICACY; HUMAN; LONG TERM CARE; NEUROIMAGING; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCHIZOPHRENIA; SENSITIZATION; ANIMAL; EARLY INTERVENTION; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANIMALS; ANTIPSYCHOTIC AGENTS; EARLY MEDICAL INTERVENTION; HUMANS; NEUROIMAGING; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 85021782269     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2017.16091016     Document Type: Review

References (103)

1. Buchanan RW, Kreyenbuhl J, Kelly DL, et al: The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36:71-93
2. Moncrieff J: Antipsychotic maintenance treatment: time to rethink? PLoS Med 2015; 12:e1001861
3. Gøtzsche PC, Young AH, Crace J: Does long term use of psychiatric drugs cause more harm than good? BMJ 2015; 350:h2435
4. Whitaker R: The case against antipsychotic drugs: a 50-year record of doing more harm than good. Med Hypotheses 2004; 62:5-13
5. Whitaker R: The Case Against Antipsychotics: A Review of Their Long-Term Side Effects. Cambridge, Mass, Mad in America Foundation, 2016
6. Wunderink L, Nieboer RM, Wiersma D, et al: Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013; 70:913-920
7. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596-601
8. Olfson M, Gerhard T, Huang C, et al: Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2015; 72:1172-1181
9. Torniainen M, Mittendorfer-Rutz E, Tanskanen A, et al: Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 2015; 41:656-663
10. Mishara AL, Goldberg TE: A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 2004; 55:1013-1022
11. Goldberg TE, Goldman RS, Burdick KE, et al: Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: Is it a practice effect? Arch Gen Psychiatry 2007; 64:1115-1122
12. Fusar-Poli P, Papanastasiou E, Stahl D, et al: Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull 2015; 41:892-899
13. Leucht S, Arbter D, Engel RR, et al: How effective are secondgeneration antipsychotic drugs? A meta-analysis of placebocontrolled trials. Mol Psychiatry 2009; 14:429-447
14. Leucht S, Hierl S, Kissling W, et al: Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012; 200:97-106
15. Rutherford BR, Pott E, Tandler JM, et al: Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiatry 2014; 71:1409-1421
16. Khin NA, Chen YF, Yang Y, et al: Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. J Clin Psychiatry 2012; 73:856-864
17. Leucht S, Kissling W, Davis JM: Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009; 39:1591-1602
18. Hegarty JD, Baldessarini RJ, Tohen M, et al: One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151:1409-1416
19. Jääskeläinen E, Juola P, Hirvonen N, et al: A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013; 39: 1296-1306
20. Carpenter WT, McGlashan TH, Strauss JS: The treatment of acute schizophrenia without drugs: an investigation of some current assumptions. Am J Psychiatry 1977; 134:14-20
21. Matthews SM, Roper MT, Mosher LR, et al: A non-neuroleptic treatment for schizophrenia: analysis of the two-year postdischarge risk of relapse. Schizophr Bull 1979; 5:322-333
22. Guttmacher MS: Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964; 10:246-261
23. Lehtinen V, Aaltonen J, Koffert T, et al: Two-year outcome in firstepisode psychosis treated according to an integrated model: Is immediate neuroleptisation always needed? Eur Psychiatry 2000; 15:312-320
24. Bola JR, Mosher LR: Treatment of acute psychosis without neuroleptics: two-year outcomes from the Soteria project. J Nerv Ment Dis 2003; 191:219-229
25. Bola JR, Lehtinen K, Aaltonen J, et al: Predicting medication-free treatment response in acute psychosis: cross-validation from the Finnish Need-Adapted Project. J Nerv Ment Dis 2006; 194:732-739
26. Huber G, Gross G, Schüttler R, et al: Longitudinal studies of schizophrenic patients. Schizophr Bull 1980; 6:592-605
27. Sohler N, Adams BG, Barnes DM, et al: Weighing the evidence for harm from long-term treatment with antipsychotic medications: A systematic review. Am J Orthopsychiatry 2016; 86:477-475
28. Wyatt RJ: Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17:325-351
29. Francey SM, Nelson B, ThompsonA, et al:Whoneeds antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophr Res 2010; 119:1-10
30. Odegard O: Pattern of discharge from Norwegian psychiatric hospitals before and after the introduction of the psychotropic drugs. Am J Psychiatry 1964; 120:772-778
31. Peterson DB, Olson GW: First admitted schizophrenics in drug era: follow-up of Anoka schizophrenic cohort, 1956-1958. Arch Gen Psychiatry 1964; 11:137-144
32. McWalter HS, Mercer R, Sutherland MM, et al: Outcomes of treatment of schizophrenia in a North-East Scottish mental hospital. Am J Psychiatry 1961; 118:529-533
33. Astrup C, Noreik K: Functional Psychoses: Diagnostic and Prognostic Models. Springfield, Ill, Charles . Thomas, 1966
34. Pritchard M: Prognosis of schizophrenia before and after pharmacotherapy, I: Short term outcome. Br J Psychiatry 1967; 113: 1345-1352
35. May PR, Tuma AH, Yale C, et al: Schizophrenia: a follow-up study of results of treatment. Arch Gen Psychiatry 1976; 33:481-486
36. May PRA, Tuma AH, Dixon WJ, et al: Schizophrenia: a follow-up study of the results of five forms of treatment. Arch Gen Psychiatry 1981; 38:776-784
37. SchoolerNR, Goldberg SC, Boothe H, et al:Oneyear after discharge: community adjustment of schizophrenic patients. Am J Psychiatry 1967; 123:986-995
38. Rappaport M, Hopkins HK, Hall K, et al: Are there schizophrenics for whom drugs may be unnecessary or contraindicated? Int Pharmacopsychiatry 1978; 13:100-111
39. Ran MS, Weng X, Chan CL, et al: Different outcomes of nevertreated and treated patients with schizophrenia: 14-year follow-up study in rural China. Br J Psychiatry 2015; 207:495-500
40. Padmavathi R, Rajkumar S, Srinivasan TN: Schizophrenic patients who were never treated: a study in an Indian urban community. Psychol Med 1998; 28:1113-1117
41. Kurihara T, Kato M, Reverger R, et al: Never-treated patients with schizophrenia in the developing country of Bali. Schizophr Res 2005; 79:307-313
42. Alem A, Kebede D, Fekadu A, et al: Clinical course and outcome of schizophrenia in a predominantly treatment-naive cohort in rural Ethiopia. Schizophr Bull 2009; 35:646-654
43. Penttilä M, Jääskeläinen E, Hirvonen N, et al: Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2014; 205: 88-94
44. Melle I, Larsen TK, Haahr U, et al: Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Arch Gen Psychiatry 2008; 65:634-640
45. Perkins DO, Gu H, Boteva K, et al: Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005; 162: 1785-1804
46. Harrow M, Jobe TH, Faull RN: Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. Psychol Med 2014; 44:3007-3016
47. Moilanen J, Haapea M, Miettunen J, et al: Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication: a 10-year follow-up of the Northern Finland 1966 Birth Cohort study. Eur Psychiatry 2013; 28:53-58
48. HarrowM, Jobe TH: Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study. J Nerv Ment Dis 2007; 195:406-414
49. Tiihonen J, Wahlbeck K, Lönnqvist J, et al: Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006; 333:224
50. Tiihonen J, Lönnqvist J, Wahlbeck K, et al: 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374:620-627
51. De Hert M, Correll CU, Cohen D: Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res 2010; 117:68-74
52. Leucht S, Tardy M, Komossa K, et al: Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379:2063-2071
53. Fenton WS, McGlashan TH: Sustained remission in drug-free schizophrenic patients. Am J Psychiatry 1987; 144:1306-1309
54. Harrison G, Hopper K, Craig T, et al: Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 2001; 178:506-517
55. HarrowM, Jobe TH, Faull RN: Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol Med 2012; 42:2145-2155
56. Wunderink L, Nienhuis FJ, Sytema S, et al: Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007; 68: 654-661
57. De Hert M, Sermon J, Geerts P, et al: The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: A systematic review and meta-analysis of randomized controlled trials with first- and secondgeneration antipsychotics. CNS Drugs 2015; 29:637-658
58. Mayoral-van Son J, de la Foz VO, Martinez-Garcia O, et al: Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study. J Clin Psychiatry 2016; 77:492-500
59. Uchida H, Suzuki T, Takeuchi H, et al:Lowdose vs standard dose of antipsychotics for relapse prevention in schizophrenia: metaanalysis. Schizophr Bull 2011; 37:788-799
60. McIntosh AM, Owens DC, Moorhead WJ, et al: Longitudinal volume reductions in people at high genetic risk of schizophrenia as they develop psychosis. Biol Psychiatry 2011; 69:953-958
61. Baaré WF, van Oel CJ, Hulshoff Pol HE, et al: Volumes of brain structures in twins discordant for schizophrenia. Arch Gen Psychiatry 2001; 58:33-40
62. Haijma SV, Van Haren N, Cahn W, et al: Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull 2013; 39:1129-1138
63. Radua J, Borgwardt S, Crescini A, et al: Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. Neurosci Biobehav Rev 2012; 36:2325-2333
64. Bogerts B, Meertz E, Schönfeldt-Bausch R: Basal ganglia and limbic system pathology in schizophrenia: A morphometric study of brain volume and shrinkage. Arch Gen Psychiatry 1985; 42:784-791
65. Bogerts B, Falkai P, Haupts M, et al: Post-mortem volume measurements of limbic system and basal ganglia structures in chronic schizophrenics: Initial results froma newbraincollection. Schizophr Res 1990; 3:295-301
66. van Haren NE, Hulshoff Pol HE, Schnack HG, et al: Focal gray matter changes in schizophrenia across the course of the illness: A 5-year follow-up study. Neuropsychopharmacology, 2007; 32: 2057-2066
67. Andreasen NC, Liu D, Ziebell S, et al: Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 2013; 170:609-615
68. Boonstra G, vanHarenNE, SchnackHG, et al: Brainvolumechanges after withdrawal of atypical antipsychotics in patients with firstepisode schizophrenia. J Clin Psychopharmacol 2011; 31:146-153
69. Toulopoulou T, Grech A, Morris RG, et al:Therelationship between volumetric brain changes and cognitive function: a family study on schizophrenia. Biol Psychiatry 2004; 56:447-453
70. Kubota M, van Haren NE, Haijma SV, et al: Association of IQ changes and progressive brain changes in patients with schizophrenia. JAMA Psychiatry 2015; 72:803-812
71. van Haren NE, Schnack HG, Cahn W, et al: Changes in cortical thickness during the course of illness in schizophrenia. Arch Gen Psychiatry 2011; 68:871-880
72. Veijola J, Guo JY, Moilanen JS, et al: Longitudinal changes in total brain volume in schizophrenia: relation to symptom severity, cognition and antipsychotic medication. PLoS One 2014; 9:e101689
73. Bora E, Murray RM: Meta-analysis of cognitive deficits in ultrahigh risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis? Schizophr Bull 2014; 40:744-755
74. Kurtz MM: Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophr Res 2005; 74:15-26
75. Weinberger DR, McClure RK: Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Arch Gen Psychiatry 2002; 59:553-558
76. Ahmed M, Cannon DM, Scanlon C, et al: Progressive brain atrophy and cortical thinning in schizophrenia after commencing clozapine treatment. 2015; 40:2409-2417
77. Arnold SE, Trojanowski JQ, Gur RE, et al: Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch Gen Psychiatry 1998; 55:225-232
78. Nishioka N, Arnold SE: Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 2004; 12:167-175
79. SelemonLD, Goldman-Rakic PS:The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 1999; 45:17-25
80. Dean CE: Antipsychotic-associated neuronal changes in the brain: toxic, therapeutic, or irrelevant to the long-term outcome of schizophrenia? Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 174-189
81. Leucht S, Cipriani A, Spineli L, et al: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multipletreatments meta-analysis. Lancet 2013; 382:951-962
82. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223
83. Correll CU, Schenk EM: Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008; 21:151-156
84. Tsai G, Goff DC, Chang RW, et al: Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998; 155:1207-1213
85. Lieberman J, Chakos M, Wu H, et al: Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry 2001; 49:487-499
86. Ho BC, Andreasen NC, Ziebell S, et al: Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 2011; 68:128-137
87. Vita A, De Peri L, Deste G, et al: The effect of antipsychotic treatment on cortical gray matter changes in schizophrenia: Does the class matter? A Meta-analysis and meta-regression of longitudinal magnetic resonance imaging studies. Biol Psychiatry 2015; 78:403-412
88. Dorph-Petersen KA, Pierri JN, Perel JM, et al: The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaquemonkeys. Neuropsychopharmacology 2005; 30:1649-1661
89. Konopaske GT, Dorph-Petersen KA, Pierri JN, et al: Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology 2007; 32:1216-1223
90. Vernon AC, Natesan S, Modo M, et al: Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol Psychiatry 2011; 69:936-944
91. Meyer U, Spoerri E, Yee BK, et al: Evaluating early preventive antipsychotic and antidepressant drug treatment in an infectionbased neurodevelopmental mouse model of schizophrenia. Schizophr Bull 2010; 36:607-623
92. Prien RF, Levine J, Switalski RW: Discontinuation of chemotherapy for chronic schizophrenics. Hosp Community Psychiatry 1971; 22:4-7
93. Chouinard G, Jones BD: Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 1980; 137:16-21
94. Muller P, Seeman P: Brain neurotransmitter receptors after longterm haloperidol: dopamine, acetylcholine, serotonin, alphanoradrenergic and naloxone receptors. Life Sci 1977; 21:1751-1758
95. Moller Nielsen I, Fjalland B, Pedersen V, et al: Pharmacology of neuroleptics upon repeated administration. Psychopharmacology (Berl) 1974; 34:95-104
96. Prien RF, Gillis RD, Caffey EM Jr: Intermittent pharmacotherapy in chronic schizophrenia.HospCommunity Psychiatry 1973; 24:317-322
97. RemingtonG, SeemanP, Feingold A, et al: "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a doubleblind, placebo-controlled trial. J Clin Psychiatry 2011; 72:1042-1048
98. Caffey EM Jr, Diamond LS, Frank TV, et al: Discontinuation or reduction of chemotherapy in chronic schizophrenics. J Chronic Dis 1964; 17:347-358
99. Olson GW, Peterson DB: Intermittent chemotherapy for chronic psychiatric inpatients. J Nerv Ment Dis 1962; 134:145-149
100. Herz MI, Glazer WM, Mostert MA, et al: Intermittent vs maintenance medication in schizophrenia: Two-year results. Arch Gen Psychiatry 1991; 48:333-339
101. Jolley AG, Hirsch SR, Morrison E, et al: Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 1990; 301:837-842
102. Lidow MS, Williams GV, Goldman-Rakic PS: The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol Sci 1998; 19:136-140
103. Castner SA, Williams GV, Goldman-Rakic PS: Reversal of working memory deficits by short-term dopamine D1 receptor stimulation. Science 2000; 287:2020-2022